Evidence map›Paper›PMID 30687063›Full record

ArticleCase reports in oncology

Rare Case of Intracardiac Renal Cell Carcinoma Metastasis with Response to Nivolumab: Case Report and Literature Review.

Jawaher Ansari, Sumaya Alhelali, Zakariya Albinmousa, Ashraf Farrag, Arwa M Ali, Mai Abdelgelil, Abdulaziz Alhamad, Ghormallah Alzahrani, Asif Ansari, John Glaholm

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Renal Cell Carcinoma Metastasis to the Left Atrium.Texas Heart Institute journal · 2022
    Article
  9. Article
  10. Renal Cell Carcinoma With Cardiac Metastases.World journal of oncology · 2021
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jawaher AnsariDepartment of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Sumaya AlhelaliPrince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
Zakariya AlbinmousaPrince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
Ashraf FarragClinical Oncology Department, Assiut University, Asyut, Egypt.
Arwa M AliMedical Oncology Department, South Egypt Cancer Institute, Asyut, Egypt.
Mai AbdelgelilClinical Oncology Department, Assiut University, Asyut, Egypt.
Abdulaziz AlhamadDepartment of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Ghormallah AlzahraniPrince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
Asif AnsariPermian Basin Kidney Center, Odessa, Texas, USA.
John GlaholmDepartment of Oncology, Royal Marsden Hospital, London, United Kingdom.
Prince Sultan University · SAAssiut University · EGRiyadh Armed Forces Hospital · SAChildren Cancer Hospital · EGRoyal Marsden Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracardiac metastases in the absence of inferior vena cava involvement is a rare occurrence in patients with metastatic renal cell carcinoma (mRCC). There is limited evidence regarding the efficacy and safety of standard treatment modalities for mRCC patients with intracardiac metastases. Presence of intracardiac metastases is known to indicate poor prognosis and may potentially increase risk of treatment-related complications. Recent advances in RCC management have integrated nivolumab, a programmed death-1 (PD-1) receptor inhibitor, as a preferred treatment option in the second-line setting after failure of prior anti-angiogenic therapy; or in combination with ipilimumab, an anti-Cytotoxic T-lymphocyte antigen-4 antibody as first-line therapy for intermediate to poor risk patients with mRCC. The efficacy and toxicity of nivolumab in patients with mRCC and intracardiac metastases has never been reported previously. We herein present the first reported case of mRCC with intracardiac metastasis and a resultant excellent response to nivolumab treatment and discuss the imaging techniques and treatment options for this rare presentation.

Indexed as

CardiacImmunotherapyIntracardiac metastasesNivolumabRenal cell carcinoma

Identifiers

PMID30687063
PMCPMC6341359
OpenAlexW2906160666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.